Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs reduced-dose combination chemotherapy in fragile patients with non-resectable pancreatic cancer
2024-514291-41-00Phase 2Authorised
- Sponsor
- Aalborg University Hospital
- Start
- Oct 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic adenocarcinoma (PDAC) comparing Gemcitabine monotherapy with Reduced-dose gemcitabine + Abraxane (2 arms). Primary endpoint: Progression Free Survival. Planned start Oct 2023; status: authorised.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-514291-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514291-41-00.